Patient characteristics and results
| Patient | Sex | Age (years) | CK-MBmax (μg/l) | Delay in thrombolysis (hours) | Reperfusion | Infarct location by ECG | Oedema location by MRI | Duration of oedema (months) |
| 1 | M | 51 | 271 | – | Yes | Ant-sep | Ant-sep | 6 |
| 2 | M | 75 | 331 | 4.0 | Yes | Ant-sep-lat | Ant-sep | 1 |
| 3 | M | 53 | 213 | 3.0 | Yes | Inf | Inf | 1 week |
| 4 | M | 74 | 383 | 3.0 | Yes | Lat | Lat | 3 |
| 5 | M | 51 | 423 | 2.0 | Yes | Ant-sep | Ant-sep | 12 |
| 6 | F | 65 | 136 | 5.0 | No | Inf | Inf | 1 |
| 7 | M | 55 | 152 | 6.0 | Yes | Ant-sep-lat | Lat | 12 |
| 8 | M | 60 | 225 | 5.0 | No | Ant-sep | Ant-sep | 6 |
| 9 | F | 45 | 136 | 1.5 | Yes | Ant-sep | Ant-sep | 6 |
| 10 | F | 53 | 607 | 4.0 | Yes | Ant-sep | Ant-sep | 12 |
Ant, anterior; CK-MBmax, maximum value of creatine kinase MB isoenzyme; Duration of oedema, the latest MRI examination showing high signal intensity areas within the myocardium; Inf, inferior; Infarct location, defined by ECGs obtained on admission; Lat, lateral; MRI, magnetic resonance imaging; Oedema location, defined by the initial MRI examination; Reperfusion, defined by ECG7; Sep, septal; Delay in thrombolysis, time from appearance of symptoms to start of thrombolytic treatment.